These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35363574)

  • 1. Acceptability of a Long-Acting, Multipurpose Vaginal Ring: Findings from a Phase I Trial in the U.S. and Dominican Republic.
    Tolley EE; Zissette S; Taylor J; Hanif H; Ju S; Schwarz J; Thurman A; Tyner D; Brache V; Doncel GF
    J Womens Health (Larchmt); 2022 Sep; 31(9):1343-1352. PubMed ID: 35363574
    [No Abstract]   [Full Text] [Related]  

  • 2. Preferred product attributes of a multipurpose vaginal ring: Findings from a phase 1 trial.
    Tolley EE; Hanif H; Thurman A; Brache V; Doncel GF
    Front Reprod Health; 2023; 5():1148134. PubMed ID: 37064825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.
    Thurman AR; Brache V; Cochon L; Ouattara LA; Chandra N; Jacot T; Yousefieh N; Clark MR; Peet M; Hanif H; Schwartz JL; Ju S; Marzinke MA; Erikson DW; Parikh U; Herold BC; Fichorova RN; Tolley E; Doncel GF
    PLoS One; 2022; 17(10):e0275794. PubMed ID: 36215267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. User evaluations offer promise for pod-intravaginal ring as a drug delivery platform: A mixed methods study of acceptability and use experiences.
    Guthrie KM; Rosen RK; Vargas SE; Getz ML; Dawson L; Guillen M; Ramirez JJ; Baum MM; Vincent KL
    PLoS One; 2018; 13(5):e0197269. PubMed ID: 29758049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acceptability of an intravaginal ring for simultaneously preventing HIV infection and pregnancy: Qualitative findings of the Kisumu Combined Ring Study, 2019.
    McLellan-Lemal E; Deaton SR; Betts JE; Ondenge K; Mudhune V; O'Connor SM; Nyagol B; Thurman AR; Doncel GF; Allen SA; Heffron R; Mugo NR;
    Contemp Clin Trials; 2022 Nov; 122():106935. PubMed ID: 36162740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model.
    Smith JM; Moss JA; Srinivasan P; Butkyavichene I; Gunawardana M; Fanter R; Miller CS; Sanchez D; Yang F; Ellis S; Zhang J; Marzinke MA; Hendrix CW; Kapoor A; Baum MM
    PLoS One; 2017; 12(10):e0185946. PubMed ID: 28982161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferred Product Attributes of Potential Multipurpose Prevention Technologies for Unintended Pregnancy and Sexually Transmitted Infections or HIV Among U.S. Women.
    Hynes JS; Sheth AN; Lathrop E; Sales JM; Haddad LB
    J Womens Health (Larchmt); 2019 May; 28(5):665-672. PubMed ID: 30615569
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
    PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Women Want Choices: Opinions from the Share.Learn.Shape Global Internet Survey About Multipurpose Prevention Technology (MPT) Products in Development.
    Friedland BA; Plagianos M; Savel C; Kallianes V; Martinez C; Begg L; Guthrie KM; Venkatasetty D; Pickett J; Haddad LB
    AIDS Behav; 2023 Jul; 27(7):2190-2204. PubMed ID: 36881183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in long-acting injectables, implants, and vaginal rings for contraception and HIV prevention.
    Krovi SA; Johnson LM; Luecke E; Achilles SL; van der Straten A
    Adv Drug Deliv Rev; 2021 Sep; 176():113849. PubMed ID: 34186143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex Vivo.
    Villegas G; Calenda G; Ugaonkar S; Zhang S; Kizima L; Mizenina O; Gettie A; Blanchard J; Cooney ML; Robbiani M; Fernández-Romero JA; Zydowsky TM; Teleshova N
    PLoS One; 2016; 11(7):e0159332. PubMed ID: 27428377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.
    Thurman AR; Schwartz JL; Brache V; Clark MR; McCormick T; Chandra N; Marzinke MA; Stanczyk FZ; Dezzutti CS; Hillier SL; Herold BC; Fichorova R; Asin SN; Rollenhagen C; Weiner D; Kiser P; Doncel GF
    PLoS One; 2018; 13(6):e0199778. PubMed ID: 29953547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Young Women's Ratings of Three Placebo Multipurpose Prevention Technologies for HIV and Pregnancy Prevention in a Randomized, Cross-Over Study in Kenya and South Africa.
    Minnis AM; Roberts ST; Agot K; Weinrib R; Ahmed K; Manenzhe K; Owino F; van der Straten A;
    AIDS Behav; 2018 Aug; 22(8):2662-2673. PubMed ID: 29560570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferences, educational messaging, and demand creation channels for multipurpose-prevention technologies (MPTs) among women in South Africa.
    Mataboge P; Mthimkhulu N; Kutywayo A; Martin CE; Mazibuko M; Kwatsha K; Makalela N; Briedenhann E; Butler V; Bothma R; Mullick S
    BMC Public Health; 2023 Oct; 23(1):2090. PubMed ID: 37880628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring.
    Thurman AR; Ravel J; Gajer P; Marzinke MA; Ouattara LA; Jacot T; Peet MM; Clark MR; Doncel GF
    Front Cell Infect Microbiol; 2022; 12():799501. PubMed ID: 35350436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current status of the female condom in Africa].
    Deniaud F
    Sante; 1997; 7(6):405-15. PubMed ID: 9503499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya.
    Mugo NR; Mudhune V; Heffron R; Thomas KK; McLellan-Lemal E; Njoroge B; Peacock S; O'Connor SM; Nyagol B; Ouma E; Ridzon R; Wiener J; Isoherranen N; Erikson DW; Ouattara LA; Yousefieh N; Jacot TA; Haaland RE; Morrison SA; Haugen HS; Thurman AR; Allen SA; Baeten JM; Samandari T; Doncel GF
    Front Reprod Health; 2023; 5():1118030. PubMed ID: 37383290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies.
    Thurman AR; Clark MR; Hurlburt JA; Doncel GF
    Int J Womens Health; 2013 Oct; 5():695-708. PubMed ID: 24174884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ring plus project: safety and acceptability of vaginal rings that protect women from unintended pregnancy.
    Schurmans C; De Baetselier I; Kestelyn E; Jespers V; Delvaux T; Agaba SK; van Loen H; Menten J; van de Wijgert J; Crucitti T;
    BMC Public Health; 2015 Apr; 15():348. PubMed ID: 25880636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next generation 3D-printed intravaginal ring for prevention of HIV and unintended pregnancy.
    Young IC; Srinivasan P; Shrivastava R; Janusziewicz R; Thorson A; Cottrell ML; Sellers RS; Sykes C; Schauer A; Little D; Kelley K; Kashuba ADM; Katz D; Pyles RB; García-Lerma JG; Vincent KL; Smith J; Benhabbour SR
    Biomaterials; 2023 Oct; 301():122260. PubMed ID: 37549505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.